Craft

Pacific Biosciences of California

Stock Price

$11.4

2023-09-01

Market Capitalization

$2.9 B

2023-09-01

Revenue

$128.3 M

FY, 2022

Pacific Biosciences of California Summary

Company Summary

Overview
Pacific Biosciences of California (PacBio, formerly known as Nanofluidics) is a company developing a platform for genetic analysis. It offers HiFi long-read sequencing technology and short-read Sequencing by Binding (SBB) technology. The company delivers solutions for various applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, etc.
Type
Public
Status
Active
Founded
2004
HQ
Menlo Park, CA, US | view all locations
Website
https://www.pacb.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Susan Kim

    Susan Kim, Chief Financial Officer

  • Michele Farmer

    Michele Farmer, Chief Accounting Officer

  • Christian Henry

    Christian Henry, President & Chief Executive Officer, Director

  • Jeff Eidel

    Jeff Eidel, Chief Commercial Officer

Operating MetricsView all

Patents (US)

221

FY, 2016

Patents Pending

187

FY, 2016

Patents (Foreign)

133

FY, 2016

LocationsView all

8 locations detected

  • Menlo Park, CA HQ

    United States

    1305 O'Brien Dr

  • Baltimore, MD

    United States

    701 E Pratt St

  • San Diego, CA

    United States

    6965 Lusk Blvd

  • Shanghai, Shang Hai Shi

    China

    Room 3256, 32F, No.222 East Yan’an Rd, Huangpu District

  • Yokohama, Kanagawa

    Japan

    Ocean Gate, Mirato Mirai 8F 3-7-1 Minatomirai, Nishi-ku

  • Singapore

    Singapore

    20 Science Park Rd, #01 22

and 2 others

Pacific Biosciences of California Financials

Summary Financials

Revenue (Q2, 2023)
$47.6M
Gross profit (Q2, 2023)
$15.5M
Net income (Q2, 2023)
($69.8M)
Cash (Q2, 2023)
$209.3M
EBIT (Q2, 2023)
($73.2M)
Enterprise value
$2.7B

Footer menu